amlx stock forecast 2025
amlx stock forecast 2025
Introduction to Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. is a commercialstage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship product, Relyvrio (also known as Albrioza in Canada), is a treatment aimed at slowing the progression of ALS. The company was founded in 2013 by Joshua Cohen and Justin Klee and is headquartered in Cambridge, Massachusetts.
Stock Analysis and Forecast for 2025
As of March 2025, the current price of AMLX is $3.20. The stock has shown significant volatility in recent periods, with a yearoveryear decrease of 82.12%. However, analysts remain optimistic about its future prospects.
ShortTerm Outlook (2025)
Price Forecast: Analysts predict that AMLX will reach an average price of $16.89 by the end of 2025, with a high estimate of $31.35 and a low estimate of $2.43. This indicates a potential increase of up to 427.95% from the current price.
Monthly Trends: In the coming months, AMLX is expected to see significant gains. For example, in March 2025, the average forecast is $23.02, with a high of $25.76 and a low of $20.54.
Technical Indicators
RSI (Relative Strength Index): The RSI value of 40.36 suggests a neutral sentiment in the short term.
MACD (Moving Average Convergence Divergence): The MACD value of 0.1466 indicates a potential sell signal.
CCI (Commodity Channel Index): The CCI value of 104.58 suggests the stock is currently oversold, which may indicate a potential buying opportunity.
LongTerm Outlook
2030 Forecast: By 2030, AMLX is projected to reach an average price of $9.43, with a high estimate of $18.85 and a low estimate of $0.0069. This represents a potential increase of up to 194.64% from the current price.
2035 Forecast: The stock is expected to reach an average price of $53.17 by 2035, indicating a significant longterm growth potential.
Conclusion
Amylyx Pharmaceuticals, Inc. (AMLX) is a highrisk, highreward stock with significant upside potential based on analyst forecasts. While the current price is relatively low, the projected growth over the next few years suggests that AMLX could be an attractive investment for those willing to take on the associated risks.
Amylyx Pharmaceuticals, Inc. is a commercialstage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship product, Relyvrio (also known as Albrioza in Canada), is a treatment aimed at slowing the progression of ALS. The company was founded in 2013 by Joshua Cohen and Justin Klee and is headquartered in Cambridge, Massachusetts.
Stock Analysis and Forecast for 2025
As of March 2025, the current price of AMLX is $3.20. The stock has shown significant volatility in recent periods, with a yearoveryear decrease of 82.12%. However, analysts remain optimistic about its future prospects.
ShortTerm Outlook (2025)
Price Forecast: Analysts predict that AMLX will reach an average price of $16.89 by the end of 2025, with a high estimate of $31.35 and a low estimate of $2.43. This indicates a potential increase of up to 427.95% from the current price.
Monthly Trends: In the coming months, AMLX is expected to see significant gains. For example, in March 2025, the average forecast is $23.02, with a high of $25.76 and a low of $20.54.
Technical Indicators
RSI (Relative Strength Index): The RSI value of 40.36 suggests a neutral sentiment in the short term.
MACD (Moving Average Convergence Divergence): The MACD value of 0.1466 indicates a potential sell signal.
CCI (Commodity Channel Index): The CCI value of 104.58 suggests the stock is currently oversold, which may indicate a potential buying opportunity.
LongTerm Outlook
2030 Forecast: By 2030, AMLX is projected to reach an average price of $9.43, with a high estimate of $18.85 and a low estimate of $0.0069. This represents a potential increase of up to 194.64% from the current price.
2035 Forecast: The stock is expected to reach an average price of $53.17 by 2035, indicating a significant longterm growth potential.
Conclusion
Amylyx Pharmaceuticals, Inc. (AMLX) is a highrisk, highreward stock with significant upside potential based on analyst forecasts. While the current price is relatively low, the projected growth over the next few years suggests that AMLX could be an attractive investment for those willing to take on the associated risks.